Revenue
2022
2023
2024
2025
MBX Biosciences, Inc. (MBX)
Price$61.72Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research & development | $79.2M | $57.4M | $28.5M | $21.4M |
| Operating expenses | $98.1M | $68.2M | $35.3M | $25.2M |
| Operating income | −$98.1M | −$68.2M | −$35.3M | −$25.2M |
| EBITDA | −$97.8M | −$68.0M | −$35.2M | −$25.7M |
| Net income | −$87.0M | −$61.9M | −$32.6M | −$26.1M |
| Basic EPSper basic share | -$2.38 | -$5.82 | -$31.96 | -$0.82 |
| Diluted EPSper diluted share | -$2.38 | -$5.82 | -$31.96 | -$0.82 |
Owners
Reported shareholders
13.87%of listed shares
Frazier Life Sciences Management, L.P.6.65M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Frazier Life Sciences Management, L.P. | 13.87%6.65M shares |
FMR LLC | 11.10%5.32M shares |
FHMLS X, L.P. / Topper James N / Heron Patrick J / Frazier Life Sciences X, L.P. / FHMLS X, L.L.C. | ≈10.89%5.22M shares |
WELLINGTON MANAGEMENT GROUP LLP | 10.38%4.98M shares |
GORDON CARL L | ≈8.35%4M shares |
SANDELL SCOTT D | ≈7.54%3.61M shares |
BASKETT FOREST | ≈7.54%3.61M shares |
Mathers Edward T | ≈7.54%3.61M shares |
NEA Management Company, LLC | 7.54%3.61M shares |
Walker Paul Edward | ≈7.54%3.61M shares |
Florence Anthony A. Jr. | ≈7.54%3.61M shares |
Behbahani Ali | ≈7.54%3.61M shares |
Makhzoumi Mohamad | ≈7.54%3.61M shares |
Chang Carmen | ≈7.54%3.61M shares |
NEA Partners 17, L.P. / New Enterprise Associates 17, L.P. / NEA 17 GP, LLC | ≈7.54%3.61M shares |
Yang Rick | ≈7.54%3.61M shares |
ORBIMED ADVISORS LLC | 7.15%3.43M shares |
BlackRock, Inc. | 6.93%3.32M shares |
Paradigm Biocapital Advisors LP | 5.23%2.51M shares |
NVP ASSOCIATES, LLC | 4.46%2.14M shares |
Percentages use 47.95M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 8, 2026Form 4 · 10b5-1 | Azoulay SalomonChief Medical Officer | SellCommon Stock | 15.0K | $38.30 | $574.6K | 14.8K |
| May 8, 2026Form 4 · 10b5-1 | Azoulay SalomonChief Medical Officer | SellCommon Stock | 55.0K | $38.38 | $2.11M | 14.8K |
| May 6, 2026Form 4 | Azoulay SalomonChief Medical Officer | SellCommon Stock | 231 | $29.54 | $6.8K | 14.8K |
| May 6, 2026Form 4 | Hawryluk P. KentPresident & CEO | SellCommon Stock | 607 | $29.54 | $17.9K | 727.7K |
| Mar 13, 2026Form 4 | Hawryluk P. KentPresident & CEO | BuyCommon Stock · indirect | 18.5K | $28.41 | $525.6K | 486.8K |